VisionPoint Advisory Group LLC Acquires Shares of 302 Danaher Co. (NYSE:DHR)

VisionPoint Advisory Group LLC acquired a new position in shares of Danaher Co. (NYSE:DHR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 302 shares of the conglomerate’s stock, valued at approximately $69,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC increased its position in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after purchasing an additional 148,251 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Danaher by 2.6% during the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the period. Flossbach Von Storch SE raised its position in shares of Danaher by 1.2% in the fourth quarter. Flossbach Von Storch SE now owns 3,710,738 shares of the conglomerate’s stock valued at $851,800,000 after buying an additional 44,490 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $209.86 on Friday. The stock has a market cap of $151.58 billion, a P/E ratio of 39.75, a price-to-earnings-growth ratio of 2.61 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock’s 50-day moving average is $226.71 and its 200-day moving average is $247.11. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the firm posted $2.09 EPS. Equities research analysts anticipate that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is presently 20.45%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. Scotiabank assumed coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research note on Thursday, October 31st. Jefferies Financial Group cut their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. JPMorgan Chase & Co. decreased their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 11.10% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.